Role of Postoperative Radiotherapy for Patients with Pathological Stage III Non-Small-Cell Lung Cancer after Curative Resection |
Kim, Mi-Young
(Department of Radiation Oncology, Seoul National University College of Medicine)
Wu, Hong-Gyun (Department of Radiation Oncology, Seoul National University College of Medicine) Kim, Hak-Jae (Department of Radiation Oncology, Seoul National University College of Medicine) Heo, Dae-Seog (Department of Internal Medicine, Seoul National University College of Medicine) Kim, Young-Whan (Department of Internal Medicine, Seoul National University College of Medicine) Kim, Dong-Wan (Department of Internal Medicine, Seoul National University College of Medicine) Lee, Se-Hoon (Department of Internal Medicine, Seoul National University College of Medicine) Kim, Joo-Hyun (Department of Internal Medicine, Seoul National University College of Medicine) Kim, Young-Tae (Department of Thoracic Surgery, Seoul National University College of Medicine) Kang, Chang-Hyun (Department of Thoracic Surgery, Seoul National University College of Medicine) |
1 | Andre F, Grunenwald D, Pignon JP, et al. Survival of patients with resected N2 non-small-cell lung cancer: evidence for a subclassification and implications. J Clin Oncol 2000;18:2981-2989 |
2 | Sawabata N, Keller SM, Matsumura A, et al. The impact of residual multi-level N2 disease after induction therapy for non-small cell lung cancer. Lung Cancer 2003;42:69-77 DOI ScienceOn |
3 | Matsuguma H, Nakahara R, Ishikawa Y, et al. Post-operative radiotherapy for patients with completely resected pathological stage IIIA-N2 non-small cell lung cancer: focusing on an effect of the number of mediastinal lymph node stations involved. Interact Cardiovasc Thorac Surg 2008;7:573-577 DOI ScienceOn |
4 | Sawyer TE, Bonner JA, Gould PM, et al. Effectiveness of postoperative irradiation in stage IIIA non-small cell lung cancer according to regression tree analyses of recurrence risks. Ann Thorac Surg 1997;64:1402-1407 DOI ScienceOn |
5 | Winton T, Livingston R, Johnson D, et al. Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer. N Engl J Med 2005;352:2589-2597 DOI ScienceOn |
6 | Arriagada R, Bergman B, Dunant A, et al. Cisplatinbased adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med 2004;350:351-360 DOI ScienceOn |
7 | Greene FL, Page DL, Fleming ID, et al. AJCC cancer staging manual. 6th ed. New York: Springer-Verlag, 2002 |
8 | Edge SB, Byrd DR, Compton CC, et al. AJCC cancer staging manual. 7th ed. New York: Springer-Verlag, 2009 |
9 | Socinski MA, Rosenman JG, Halle J, et al. Doseescalating conformal thoracic radiation therapy with induction and concurrent carboplatin/paclitaxel in unresectable stage IIIA/B nonsmall cell lung carcinoma: a modified phase I/II trial. Cancer 2001;92:1213-1223 DOI ScienceOn |
10 | Byhardt RW, Martin L, Pajak TF, Shin KH, Emami B, Cox JD. The influence of field size and other treatment factors on pulmonary toxicity following hyperfractionated irradiation for inoperable non-small cell lung cancer (NSCLC): analysis of a Radiation Therapy Oncology Group (RTOG) protocol. Int J Radiat Oncol Biol Phys 1993;27:537-544 DOI ScienceOn |
11 | Rosenman JG, Halle JS, Socinski MA, et al. High-dose conformal radiotherapy for treatment of stage IIIA/IIIB non-small-cell lung cancer: technical issues and results of a phase I/II trial. Int J Radiat Oncol Biol Phys 2002;54:348-356 DOI ScienceOn |
12 | Kong FM, Ten Haken RK, Schipper MJ, et al. Highdose radiation improved local tumor control and overall survival in patients with inoperable/unresectable non-small-cell lung cancer: long-term results of a radiation dose escalation study. Int J Radiat Oncol Biol Phys 2005;63:324-333 DOI ScienceOn |
13 | Spoelstra FO, Senan S, Le Pechoux C, et al. Variations in target volume definition for postoperative radiotherapy in stage III non-small-cell lung cancer: analysis of an international contouring study. Int J Radiat Oncol Biol Phys 2010;76:1106-1113 DOI ScienceOn |
14 | Keller SM, Vangel MG, Wagner H, et al. Prolonged survival in patients with resected non-small cell lung cancer and single-level N2 disease. J Thorac Cardiovasc Surg 2004;128:130-137 DOI ScienceOn |
15 | Keller SM, Adak S, Wagner H, et al. A randomized trial of postoperative adjuvant therapy in patients with completely resected stage II or IIIA non-small-cell lung cancer. Eastern Cooperative Oncology Group. N Engl J Med 2000;343:1217-1222 DOI ScienceOn |
16 | Fry WA, Phillips JL, Menck HR. Ten-year survey of lung cancer treatment and survival in hospitals in the United States: a national cancer data base report. Cancer 1999;86:1867-1876 DOI ScienceOn |
17 | Postoperative radiotherapy in non-small-cell lung cancer: systematic review and meta-analysis of individual patient data from nine randomised controlled trials. PORT Meta-analysis Trialists Group. Lancet 1998;352:257-263 DOI ScienceOn |
18 | Lally BE, Zelterman D, Colasanto JM, Haffty BG, Detterbeck FC, Wilson LD. Postoperative radiotherapy for stage II or III non-small-cell lung cancer using the surveillance, epidemiology, and end results database. J Clin Oncol 2006;24:2998-3006 DOI ScienceOn |
19 | Bradley JD, Paulus R, Graham MV, et al. Phase II trial of postoperative adjuvant paclitaxel/carboplatin and thoracic radiotherapy in resected stage II and IIIA non-small-cell lung cancer: promising long-term results of the Radiation Therapy Oncology Group--RTOG 9705. J Clin Oncol 2005;23:3480-3487 DOI ScienceOn |
20 | Feng QF, Wang M, Wang LJ, et al. A study of postoperative radiotherapy in patients with non-small-cell lung cancer: a randomized trial. Int J Radiat Oncol Biol Phys 2000;47:925-929 DOI ScienceOn |